Business
Investor Update Agenda
Investor Update Agenda.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6976O Scancell Holdings Plc 24 September 2013 \n \n\nScancell Holdings Plc\n('Scancell')\n \nInvestor Update Agenda\n \n \nScancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:\n \n\n\n\n\nLocation\n\n\nFTI Consulting\nHolborn Gate\n26 Southampton Buildings\nLondon, WC2A 1PB\n \n\n\n\n\n10.45\n\n\nRegistration with refreshments\n \n\n\n\n\n11.00\n\n\nIntroduction \nDavid Evans, Scancell Non-Executive Chairman\n \n\n\n\n\n11.05\n\n\nCancer immunotherapy\nProf Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University \nof Manchester \n \n\n\n\n\n11.20\n\n\nScancell corporate update\nDr Richard Goodfellow, Joint CEO of Scancell\n \n\n\n\n\n11.30\n\n\nSCIB1 trial update and introduction to Moditope™ \nProf Lindy Durrant, Joint CEO of Scancell \n \n\n\n\n\n11.45\n\n\nQ&A\n \n\n\n\n\n12.00\n\n\nInteractive panel discussion\nLed by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital\n \nPanellists include:\n \nProf Lindy Durrant, \nProf Peter Stern,\nDr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University\nand Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton\n \n\n\n\n\n12.45\n\n\nBuffet lunch\n \n\n\n\n\n13.30\n\n\nClose\n \n\n\n\n\n \n \nFor Further Information:\n \n\n\n\n\nDr Richard Goodfellow, Joint CEO\nProfessor Lindy Durrant, Joint CEO \n\n\nScancell Holdings Plc\nScancell Holdings Plc\n\n\n+ 44 (0) 20 7831 3113\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCamilla Hume/Stephen Keys\n\n\nCenkos Securities\n\n\n+ 44 (0) 20 7397 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Eleanor Clarke\n\n\nFTI Consulting\n\n\n+ 44 (0) 20 7831 3113\n\n\n\n\n \nAbout Scancell\n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which mi...